Von Willebrand's disease and angiodysplasia treated with thalidomide.
A 54-year-old man with type IIB VWD and severe angiodysplasia had such a large blood loss from the bowel that it was difficult to keep up with transfusion requirements. Treatment with factor eight concentrate barely slowed the loss. D.D.A.V.P., Octreotide, and recombinant activated Factor VII, tried separately, were ineffective. The use of Thalidomide at a dose of 150 mg daily has rendered him free from blood loss for the last six months and we suggest would be worth a trial in similar cases.
Hirri
H M
HM
Portsmouth Hospitals NHS Trust, Portsmouth, UK. Hussain.Hirri@porthosp.nhs.uk
Green
P J
PJ
Lindsay
J
J
D016888:Angiodysplasia / Q000150:complications / Q000188:drug therapy*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome; D014842:von Willebrand Diseases / Q000150:complications / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D013792:Thalidomide